SGLT2 inhibitors are a popular class of diabetes drugs first introduced in 2013, which now account for more than $2.5 billion in annual sales.
By reducing a certain protein, these medications force the kidneys to flush glucose out of the system rather than absorb it. However, this altering of the body’s natural process may come at a price.
In recent years, SGLT2 drugs like Invokana, Farxiga and Jardiance have been linked to kidney and bladder cancer in a number of studies:
Patients who’ve been diagnosed with bladder or kidney cancer after taking Invokana, Jardiance or Farxiga may be entitled to significant compensation to help with the associated medical costs, pain, suffering and other losses.
The makers of these medications are liable since they’ve known about the dangers for years but have failed to properly warn doctors or consumers.
The cancer risks from SGLT2 drugs first surfaced before 2012 in early clinical trials. Infact, the FDA only granted approval with the condition that drug makers would conduct additional safety testing called post-marketing studies.
However, none of the manufacturers have added warnings about cancer in the years since, despite numerous studies suggesting a risk.
If you or a loved one were diagnosed with kidney or bladder cancer after taking these diabetes medications, contact us today to speak directly with a lawyer about your rights.
Bladder and kidney cancer are among the most common forms affecting people in the United States, and usually have high rates of treatment success. However, it’s important for those at risk to know and identify the symptoms, and speak with their doctor about treatment options.
Bladder cancer is the 6th most commonly diagnosed type of cancer among Americans, and usually affects males between the ages of 65 and 85. The three types are transitional cell carcinoma, squamous cell carcinoma and adenocarcinom.
The most common symptoms of bladder cancer include:
Treatment of bladder cancer may include chemotherapy, radiation therapy, surgery or immunotherapy. With these, survival can be as high as 77%.
Kidney cancer is the 7th most common form of cancer in the United States, and may affect men and women of all ages. The two most common types are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC).
The most common symptoms of kidney cancer include:
The most common treatment for kidney cancer is surgery to remove the affected kidney or part of it. This is because kidney cancer usually doesn’t respond to either radiation therapy or chemotherapy. Overall, the survival rate is around 73%, although it can be as high as 92% in cases where the cancer does not spread beyond the kidney.
While the significant effects of cancer mean those affected may be entitled to substantial compensation, the process of filing a claim is rather easy and risk free.
First, with one call or a few clicks, you’ll be in touch with a DrugNews patient advocate that can answer questions about the latest diabetes drug cancer studies, the current litigation, and whether your case may qualify.
After a few short questions, we’ll have one of our lawyers who specializes in Invokana cancer litigation give you a call to talk more about your case specifically. They’ll explain more about gathering records, filing a claim, and the timeline of the litigation process.
Throughout the process, your lawyer will keep you updated on the status of your case, and any upcoming hearings or settlement opportunities.
Above all, you won’t owe anything to your lawyer for case costs or attorney’s fees unless they obtain an award for you. Contact us today for more info and to see how we can help your family.
Speak with a lawyer who specializes in the diabetes medication litigation.
Thank you for contacting DrugNews. Your inquiry has been forwarded to one of our Patient Advocates. A representative should be in touch with you in less than 24 hours but hopefully much sooner.
For immediate information, you can reach us on our 24/7 Defective Drug Hotline at 1-888-391-1315.
Oops! Something went wrong while submitting the form :(